Neovasc Inc (NASDAQ:NVCN) recently revealed the highlights from EuroPCR – annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology (ESC). The company, known for developing minimally invasive transcatheter mitral valve replacement technologies also announced its first-quarter 2018 results.
Neovasc Management Discuss Tiara & Reducer With Physicians
During the EuroPCR that took place at the Palais des Congres in Paris, France in between May 22 and 25, the company management carried out numerous discussions with the European physicians related to participating in the ongoing Tiara clinical trials or using the Reducer from Neovasc for treating patients with refractory angina. The Chief Executive Officer of Neovasc, Fred Colen said, “We had a successful and engaging meeting with investigators in our Tiara-II trial regarding clinical results to-date, optimal screening process, best practices for implantation, and a direct comparison of published Tiara clinical results with results from mitral clipping procedures.”
Colen added that the company also revealed the presentation results of their first animal feasibility study for the transeptal version of Tiara and collected numerous feedback, input, updates through discussions from the investigators. Neovasc’s Dr. Shmuel Banai and Dr. Stephan Verheye in their symposium on Reducer demonstrated presentations from the physicians who talked about their experiences with the Reducer.
Neovasc Announces First Quarter 2018 Results
The specialty medical device company, known for developing, manufacturing and marketing products for the cardiovascular marketplace recently announced the financial results for the first-quarter of this year. The CEO of the company said that the period was quite challenging for its shareholders, but the company managed to improve its financial position. He said that Neovasc received $12.3 million in proceeds from investor-initiated exercises of Series C warrants issued in November last year as a part of the public offering.
According to Colen, the additional capital Neovasc has received will be used to support the clinical and operating activities of the company scheduled to start in early 2019 which includes achieving further clinical milestones for Tiara as well as increasing the demand for Reducer in the European market. As per the company reports, the Tiara mitral valve has already established itself as a viable clinical treatment in around 56 patients.